{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:16:25Z","timestamp":1782245785034,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,18]]},"DOI":"10.7759\/cureus.33939","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T23:55:31Z","timestamp":1674086131000},"source":"Crossref","is-referenced-by-count":27,"title":["Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk"],"prefix":"10.7759","author":[{"given":"Bains","family":"Jasleen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gupta K","family":"Vishal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malepati","family":"Sameera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molla","family":"Fahad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O'Brien","family":"Brendan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santander","family":"Deion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Pemminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142243","article-title":"Pharmacological treatment of hyperglycemia in type 2 diabetes","volume":"131","author":"Taylor SI","year":"2021","unstructured":"Taylor SI, Yazdi ZS, Beitelshees AL. Pharmacological treatment of hyperglycemia in type 2 diabetes. J Clin Invest. 2021, 131:10.1172\/JCI142243","journal-title":"J Clin Invest"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg T","year":"2018","unstructured":"Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018, 61:2079-86. 10.1007\/s00125-018-4654-7","journal-title":"Diabetologia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.01.011","article-title":"Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: a systematic review and meta-analysis","volume":"44","author":"Cho YK","year":"2018","unstructured":"Cho YK, Kang YM, Lee SE, et al.. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2018, 44:393-401. 10.1016\/j.diabet.2018.01.011","journal-title":"Diabetes Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910822","article-title":"Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists","volume":"22","author":"Winiarska A","year":"2021","unstructured":"Winiarska A, Knysak M, Nabrdalik K, Gumprecht J, Stomp\u00f3r T. Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists. Int J Mol Sci. 2021, 22:10822. 10.3390\/ijms221910822","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ph13110379","article-title":"Perspective of SGLT2 inhibition in treatment of conditions connected to neuronal loss: focus on Alzheimer\u2019s disease and ischemia-related brain injury","volume":"13","author":"Wici\u0144ski M","year":"2020","unstructured":"Wici\u0144ski M, W\u00f3dkiewicz E, G\u00f3rski K, Walczak M, Malinowski B. Perspective of SGLT2 inhibition in treatment of conditions connected to neuronal loss: focus on Alzheimer\u2019s disease and ischemia-related brain injury. Pharmaceuticals (Basel). 2020, 13:379. 10.3390\/ph13110379","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/20406223221086996","article-title":"Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review","volume":"13","author":"Tharmaraja T","year":"2022","unstructured":"Tharmaraja T, Ho JS, Sia CH, et al.. Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review. Ther Adv Chronic Dis. 2022, 13:10.1177\/20406223221086996","journal-title":"Ther Adv Chronic Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.09.008","article-title":"Potential therapeutic effects of sodium glucose-linked cotransporter 2 inhibitors in stroke","volume":"42","author":"Al Hamed FA","year":"2020","unstructured":"Al Hamed FA, Elewa H. Potential therapeutic effects of sodium glucose-linked cotransporter 2 inhibitors in stroke. Clin Ther. 2020, 42:e242-9. 10.1016\/j.clinthera.2020.09.008","journal-title":"Clin Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12548","article-title":"Empagliflozin attenuates transient cerebral ischemia\/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway","volume":"34","author":"Amin EF","year":"2020","unstructured":"Amin EF, Rifaai RA, Abdel-Latif RG. Empagliflozin attenuates transient cerebral ischemia\/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway. Fundam Clin Pharmacol. 2020, 34:548-58. 10.1111\/fcp.12548","journal-title":"Fundam Clin Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-018-1086-4","article-title":"Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy","volume":"18","author":"Erdogan MA","year":"2018","unstructured":"Erdogan MA, Yusuf D, Christy J, Solmaz V, Erdogan A, Taskiran E, Erbas O. Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy. BMC Neurol. 2018, 18:81. 10.1186\/s12883-018-1086-4","journal-title":"BMC Neurol"},{"key":"ref10","unstructured":"Drug class overview. sodium-glucose cotransporter-2 (SGLT2) inhibitors. (2022). Accessed: 2022: https:\/\/www.clinicalkey.com\/#!\/content\/drug_class_overview\/79-s2.0-1522667."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink HJ","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016, 134:752-72. 10.1161\/CIRCULATIONAHA.116.021887","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01430-3","article-title":"SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs","volume":"20","author":"Giugliano D","year":"2021","unstructured":"Giugliano D, Longo M, Scappaticcio L, Bellastella G, Maiorino MI, Esposito K. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol. 2021, 20:236. 10.1186\/s12933-021-01430-3","journal-title":"Cardiovasc Diabetol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018245","article-title":"Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis","volume":"98","author":"Zou CY","year":"2019","unstructured":"Zou CY, Liu XK, Sang YQ, Wang B, Liang J. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis. Medicine (Baltimore). 2019, 98:e18245. 10.1097\/MD.0000000000018245","journal-title":"Medicine (Baltimore)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstr\u00e5le M","year":"2014","unstructured":"Ridderstr\u00e5le M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. EMPA-REG H2H-SU trial investigators: Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014, 2:691-700. 10.1016\/S2213-8587(14)70120-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi SE","year":"2015","unstructured":"Inzucchi SE, Zinman B, Wanner C, et al.. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015, 12:90-100. 10.1177\/1479164114559852","journal-title":"Diab Vasc Dis Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.724405","article-title":"Association between SGLT2is and cardiovascular and respiratory diseases: a meta-analysis of large trials","volume":"12","author":"Yin DG","year":"2021","unstructured":"Yin DG, Qiu M, Duan XY. Association between SGLT2is and cardiovascular and respiratory diseases: a meta-analysis of large trials. Front Pharmacol. 2021, 12:724405. 10.3389\/fphar.2021.724405","journal-title":"Front Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0657-8","article-title":"SGLT2 inhibitors: Cardiovascular benefits beyond HbA1c-translating evidence into practice","volume":"10","author":"Ali A","year":"2019","unstructured":"Ali A, Bain S, Hicks D, et al.. SGLT2 inhibitors: Cardiovascular benefits beyond HbA1c-translating evidence into practice. Diabetes Ther. 2019, 10:1595-622. 10.1007\/s13300-019-0657-8","journal-title":"Diabetes Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02644-x","article-title":"Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors","volume":"73","author":"Qiu M","year":"2021","unstructured":"Qiu M, Ding LL, Zhan ZL, Liu SY. Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors. Endocrine. 2021, 73:31-6. 10.1007\/s12020-021-02644-x","journal-title":"Endocrine"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial","volume":"143","author":"Nassif ME","year":"2021","unstructured":"Nassif ME, Qintar M, Windsor SL, et al.. Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation. 2021, 143:1673-86. 10.1161\/CIRCULATIONAHA.120.052503","journal-title":"Circulation"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.06.005","article-title":"SGLT2 inhibition and glucagon secretion in humans","volume":"44","author":"Saponaro C","year":"2018","unstructured":"Saponaro C, Pattou F, Bonner C. SGLT2 inhibition and glucagon secretion in humans. Diabetes Metab. 2018, 44:383-5. 10.1016\/j.diabet.2018.06.005","journal-title":"Diabetes Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner C","year":"2015","unstructured":"Bonner C, Kerr-Conte J, Gmyr V, et al.. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015, 21:512-7. 10.1038\/nm.3828","journal-title":"Nat Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2337\/db19-0888","article-title":"Interindividual heterogeneity of SGLT2 expression and function in human pancreatic islets","volume":"69","author":"Saponaro C","year":"2020","unstructured":"Saponaro C, M\u00fchlemann M, Acosta-Montalvo A, et al.. Interindividual heterogeneity of SGLT2 expression and function in human pancreatic islets. Diabetes. 2020, 69:902-14. 10.2337\/db19-0888","journal-title":"Diabetes"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13400","article-title":"Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic \u03b2-cells in db\/db mice: The earlier and longer, the better","volume":"20","author":"Kimura T","year":"2018","unstructured":"Kimura T, Obata A, Shimoda M, et al.. Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic \u03b2-cells in db\/db mice: The earlier and longer, the better. Diabetes Obes Metab. 2018, 20:2442-57. 10.1111\/dom.13400","journal-title":"Diabetes Obes Metab"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.10.010","article-title":"The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db\/db mice both as monotherapy and in combination with linagliptin","volume":"65","author":"Kern M","year":"2016","unstructured":"Kern M, Kl\u00f6ting N, Mark M, Mayoux E, Klein T, Bl\u00fcher M. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db\/db mice both as monotherapy and in combination with linagliptin. Metabolism. 2016, 65:114-23. 10.1016\/j.metabol.2015.10.010","journal-title":"Metabolism"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147391","article-title":"The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic \u03b2-cell mass and glucose homeostasis in type 1 diabetes","volume":"11","author":"Cheng ST","year":"2016","unstructured":"Cheng ST, Chen L, Li SY, Mayoux E, Leung PS. The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic \u03b2-cell mass and glucose homeostasis in type 1 diabetes. PLoS One. 2016, 11:e0147391. 10.1371\/journal.pone.0147391","journal-title":"PLoS One"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"DEPICT-1 Investigators Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT- 1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona P","year":"2017","unstructured":"Dandona P, Mathieu C, Phillip M, et al.. DEPICT-1 Investigators Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT- 1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017, 5:864-76. 10.1016\/S2213-8587(17)30308-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2020.102173","article-title":"SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review","volume":"6","author":"Dwinata M","year":"2020","unstructured":"Dwinata M, Putera DD, Hasan I, Raharjo M. SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review. Clin Exp Hepatol. 2020, 6:339-46. 10.5114\/ceh.2020.102173","journal-title":"Clin Exp Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0447-8","article-title":"There is a close association between the recovery of liver injury and glycemic control after SGLT2 inhibitor treatment in Japanese subjects with type 2 diabetes: a retrospective clinical study","volume":"9","author":"Kinoshita T","year":"2018","unstructured":"Kinoshita T, Shimoda M, Sanada J, et al.. There is a close association between the recovery of liver injury and glycemic control after SGLT2 inhibitor treatment in Japanese subjects with type 2 diabetes: a retrospective clinical study. Diabetes Ther. 2018, 9:1569-80. 10.1007\/s13300-018-0447-8","journal-title":"Diabetes Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13907","article-title":"Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes","volume":"22","author":"Gastaldelli A","year":"2020","unstructured":"Gastaldelli A, Repetto E, Guja C, Hardy E, Han J, Jabbour SA, Ferrannini E. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes Obes Metab. 2020, 22:393-403. 10.1111\/dom.13907","journal-title":"Diabetes Obes Metab"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13480","article-title":"Serum biomarkers can predict a change in liver fibrosis 1\u00a0year after lifestyle intervention for biopsy-proven NASH","volume":"37","author":"Vilar-Gomez E","year":"2017","unstructured":"Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, et al.. Serum biomarkers can predict a change in liver fibrosis 1\u00a0year after lifestyle intervention for biopsy-proven NASH. Liver Int. 2017, 37:1887-96. 10.1111\/liv.13480","journal-title":"Liver Int"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku A","year":"2019","unstructured":"Latva-Rasku A, Honka MJ, Kullberg J, et al.. The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients. Diabetes Care. 2019, 42:931-7. 10.2337\/dc18-1569","journal-title":"Diabetes Care"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/cld.714","article-title":"SGLT2 inhibitors and cirrhosis: a unique perspective on the comanagement of diabetes mellitus and ascites","volume":"11","author":"Saffo S","year":"2018","unstructured":"Saffo S, Taddei T. SGLT2 inhibitors and cirrhosis: a unique perspective on the comanagement of diabetes mellitus and ascites. Clin Liver Dis (Hoboken). 2018, 11:141-4. 10.1002\/cld.714","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55060268","article-title":"SGLT2 inhibitors: nephroprotective efficacy and side effects","volume":"55","author":"Garofalo C","year":"2019","unstructured":"Garofalo C, Borrelli S, Liberti ME, et al.. SGLT2 inhibitors: nephroprotective efficacy and side effects. Medicina (Kaunas). 2019, 55:268. 10.3390\/medicina55060268","journal-title":"Medicina (Kaunas)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094416","article-title":"Multi-organ protective effects of sodium glucose cotransporter 2 inhibitors","volume":"22","author":"Yanai H","year":"2021","unstructured":"Yanai H, Hakoshima M, Adachi H, Katsuyama H. Multi-organ protective effects of sodium glucose cotransporter 2 inhibitors. Int J Mol Sci. 2021, 22:4416. 10.3390\/ijms22094416","journal-title":"Int J Mol Sci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1177\/20420188221090001","article-title":"Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?","volume":"13","author":"Ujjawal A","year":"2022","unstructured":"Ujjawal A, Schreiber B, Verma A. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?. Ther Adv Endocrinol Metab. 2022, 13:10.1177\/20420188221090001","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13650","article-title":"A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors","volume":"21 Suppl 2","author":"Brown E","year":"2019","unstructured":"Brown E, Rajeev SP, Cuthbertson DJ, Wilding JP. A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019, 21 Suppl 2:9-18. 10.1111\/dom.13650","journal-title":"Diabetes Obes Metab"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2019.0208","article-title":"Use of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and abdominal obesity: an Asian perspective and expert recommendations","volume":"44","author":"Sheu WH","year":"2020","unstructured":"Sheu WH, Chan SP, Matawaran BJ, et al.. Use of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and abdominal obesity: an Asian perspective and expert recommendations. Diabetes Metab J. 2020, 44:11-32. 10.4093\/dmj.2019.0208","journal-title":"Diabetes Metab J"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.37.1.2701","article-title":"SGLT 2 Inhibitors; glycemic control, weight loss and safety profile in patients with type 2 diabetes, at Medicell Institute (MIDEM)","volume":"37","author":"Sohail E","year":"2021","unstructured":"Sohail E, Ahsan T, Ghaus S, Aijaz W. SGLT 2 Inhibitors; glycemic control, weight loss and safety profile in patients with type 2 diabetes, at Medicell Institute (MIDEM). Pak J Med Sci. 2021, 37:87-92. 10.12669\/pjms.37.1.2701","journal-title":"Pak J Med Sci"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira MJ","year":"2019","unstructured":"Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019, 79:219-30. 10.1007\/s40265-019-1057-0","journal-title":"Drugs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/132075-sodium-glucose-cotransporter-2-sglt2-inhibitors-benefits-versus-risk","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:21Z","timestamp":1707508101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/132075-sodium-glucose-cotransporter-2-sglt2-inhibitors-benefits-versus-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.33939","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,18]]}}}